Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""fms-Like Tyrosine Kinase 3"" wg kryterium: Temat


Tytuł :
FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
Autorzy :
Loschi M; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nice, 06200 Nice, France.; Université Cote d'Azur, 06108 Nice, France.; Centre Méditerranéen de Médecine Moléculaire, 06204 Nice, France.
Sammut R; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nice, 06200 Nice, France.
Chiche E; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nice, 06200 Nice, France.
Cluzeau T; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nice, 06200 Nice, France.; Université Cote d'Azur, 06108 Nice, France.; Centre Méditerranéen de Médecine Moléculaire, 06204 Nice, France.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 30; Vol. 22 (11). Date of Electronic Publication: 2021 May 30.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Drug Resistance, Neoplasm/*genetics
Leukemia, Myeloid, Acute/*therapy
Protein Kinase Inhibitors/*therapeutic use
fms-Like Tyrosine Kinase 3/*genetics
Clinical Trials as Topic ; Databases, Factual ; Gene Expression ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Mutation ; Recurrence ; Stem Cell Transplantation/methods ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Autorzy :
Joshi SK; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Department of Physiology & Pharmacology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Sharzehi S; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Cell, Development, & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
Pittsenbarger J; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Bottomly D; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
Tognon CE; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
McWeeney SK; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Cell, Development, & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Cell, Development, & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Jul 01; Vol. 96 (7), pp. E226-E229. Date of Electronic Publication: 2021 Apr 13.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural
MeSH Terms :
Drug Resistance, Neoplasm*
Aniline Compounds/*pharmacology
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrazines/*pharmacology
fms-Like Tyrosine Kinase 3/*genetics
Cell Line, Tumor ; Humans ; Leukemia, Myeloid, Acute/genetics ; Models, Molecular ; Mutation/drug effects ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors
Raport
Tytuł :
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
Autorzy :
Zeng Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ly C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jun; Vol. 100 (6), pp. 1485-1496. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji :
Journal Article
MeSH Terms :
Cyclin-Dependent Kinase 4/*antagonists & inhibitors
Cyclin-Dependent Kinase 6/*antagonists & inhibitors
Leukemia, Myeloid, Acute/*drug therapy
Neoplastic Stem Cells/*drug effects
Protein Kinase Inhibitors/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Mice, Inbred NOD ; Mice, SCID ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Protein Kinase Inhibitors/therapeutic use ; Proteomics ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.
Autorzy :
Young DJ; Department of Oncology.; Department of Pediatrics, and.
Nguyen B; Department of Oncology.
Zhu R; Department of Oncology.
Seo J; Department of Oncology.
Li L; Department of Oncology.
Levis MJ; Department of Oncology.
Pratz KW; Department of Oncology.
Duffield AS; Department of Oncology.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Small D; Department of Oncology.; Department of Pediatrics, and.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 May 11; Vol. 5 (9), pp. 2285-2293.
Typ publikacji :
Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
fms-Like Tyrosine Kinase 3*/genetics
Humans ; Mutation ; Signal Transduction ; Tandem Repeat Sequences
Czasopismo naukowe
Tytuł :
Discovery of a Potent and Selective FLT3 Inhibitor ( Z )- N -(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H -pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.
Autorzy :
Wang J; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Pan X; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Song Y; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Liu J; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Ma F; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P.R. China.
Wang P; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Liu Y; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Zhao L; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Kang D; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Hu L; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P.R. China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Apr 22; Vol. 64 (8), pp. 4870-4890. Date of Electronic Publication: 2021 Apr 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
Protein Kinase Inhibitors/*chemistry
Pyrazoles/*chemistry
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Apoptosis/drug effects ; Binding Sites ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Resistance, Neoplasm/drug effects ; G1 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Mice ; Mice, Nude ; Molecular Docking Simulation ; Mutation ; Protein Kinase Inhibitors/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/metabolism ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Signal Transduction/drug effects ; Structure-Activity Relationship ; Xenograft Model Antitumor Assays ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.
Autorzy :
Wang Z; School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China.
Cai J; School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China.
Cheng J; School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China.
Yang W; School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China.
Zhu Y; School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.
Li H; School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China.
Lu T; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P.R. China.
Chen Y; Laboratory of Molecular Design and Drug Discovery, China Pharmaceutical University, Nanjing, 211198, P.R. China.
Lu S; School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Mar 25; Vol. 64 (6), pp. 2878-2900. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Drug Resistance, Neoplasm/*drug effects
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Small Molecule Libraries/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Drug Discovery ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Models, Molecular ; Mutation/drug effects ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/therapeutic use ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/therapeutic use ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
Autorzy :
Vela-Ojeda J; Departamento de Hematología, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México; Unidad de Investigación de Medicina Traslacional en Enfermedades Hemato-Oncologicas, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Ciudad de México, México. Electronic address: .
Cardenas PV; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Ciudad de México, México.
Garcia-Ruiz Esparza MA; Departamento de Hematología, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Montiel Cervantes LA; Departamento de Hematología, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México; Unidad de Investigación de Medicina Traslacional en Enfermedades Hemato-Oncologicas, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Ciudad de México, México.
Chavez JG; Departamento de Hematología, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Caballero AH; Departamento de Hematología, Unidad Médica de Alta Especialidad, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Majluf-Cruz A; Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Vega-López A; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Ciudad de México, México.
Reyes-Maldonado E; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Ciudad de México, México.
Pokaż więcej
Źródło :
Archives of medical research [Arch Med Res] 2021 Feb; Vol. 52 (2), pp. 217-223. Date of Electronic Publication: 2020 Oct 24.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute/*metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
fms-Like Tyrosine Kinase 3/*metabolism
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Mutation ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Prognosis ; Young Adult ; fms-Like Tyrosine Kinase 3/biosynthesis ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Autorzy :
Marconi G; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy. Electronic address: .
De Polo S; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Martinelli G; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Nanni J; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Bertamini L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
Talami A; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Olivi M; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
Ragaini S; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
Abbenante MC; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Department of Haematology and Stem Cell Transplantation Unit, IRCCS 'Casa Sollievo della Sofferenza' Hospital, San Giovanni Rotondo, Italy.
Sartor C; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Ottaviani E; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy.
Bochicchio MT; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Parisi S; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy.
Fontana MC; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Cristiano G; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Raffini M; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Baldazzi C; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Testoni N; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Bonifazi F; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy.
Paolini S; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy.
Curti A; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy.
Cavo M; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy.
Papayannidis C; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy. Electronic address: .
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2021 Feb; Vol. 101, pp. 106497. Date of Electronic Publication: 2020 Dec 25.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/enzymology
Leukemia, Myeloid, Acute*/genetics
Mutation*
Quality of Life*
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
fms-Like Tyrosine Kinase 3*/genetics
fms-Like Tyrosine Kinase 3*/metabolism
Antineoplastic Agents/*administration & dosage
Protein Kinase Inhibitors/*administration & dosage
Adolescent ; Adult ; Aged ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
Autorzy :
Kim HJ; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
Ryu H; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
Choi HK; Department of Medicinal Chemistry, Jungwon University, Goesan, Republic of Korea.
Song JY; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
Hwang SG; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
Ahn J; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Feb; Vol. 41 (2), pp. 731-737.
Typ publikacji :
Journal Article
MeSH Terms :
Tandem Repeat Sequences*
Antineoplastic Agents/*pharmacology
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; DNA Damage ; DNA Repair/drug effects ; HL-60 Cells ; Humans ; Leukemia, Myeloid, Acute/enzymology ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; STAT5 Transcription Factor/metabolism ; Signal Transduction ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Autorzy :
Long Y; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Yu M; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Ochnik AM; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Karanjia JD; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Basnet SK; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Kebede AA; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Kou L; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
Wang S; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 05; Vol. 213, pp. 113215. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji :
Journal Article
MeSH Terms :
Amines/*pharmacology
Antineoplastic Agents/*pharmacology
Aza Compounds/*pharmacology
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Amines/chemical synthesis ; Amines/chemistry ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Aza Compounds/chemical synthesis ; Aza Compounds/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Discovery ; Drug Screening Assays, Antitumor ; Humans ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment.
Autorzy :
Le Q; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hadland B; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA.; Children's Oncology Group, Monrovia, CA, USA.
Bernstein I; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Department of Pediatrics, University of Washington, Seattle, WA, USA. .; Children's Oncology Group, Monrovia, CA, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Feb; Vol. 35 (2), pp. 601-605. Date of Electronic Publication: 2020 Jun 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm*
Mutation*
Benzothiazoles/*pharmacology
Endothelial Cells/*cytology
Leukemia, Myeloid, Acute/*drug therapy
Phenylurea Compounds/*pharmacology
Receptors, Notch/*antagonists & inhibitors
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Endothelial Cells/metabolism ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Tumor Cells, Cultured ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
Autorzy :
Marensi V; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Keeshan KR; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
MacEwan DJ; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom. Electronic address: .
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2021 Jan; Vol. 183, pp. 114348. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Mutation/*genetics
Protein Kinase Inhibitors/*therapeutic use
fms-Like Tyrosine Kinase 3/*genetics
Amino Acid Sequence ; Animals ; Benzothiazoles/pharmacology ; Benzothiazoles/therapeutic use ; Clinical Trials as Topic/methods ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/physiology ; Humans ; Leukemia, Myeloid, Acute/metabolism ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Structure, Secondary ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
Autorzy :
Miao H; Department of Pathology, University of Michigan, Ann Arbor, MI.
Kim E; Department of Pathology, University of Michigan, Ann Arbor, MI.
Chen D; Department of Pathology, University of Michigan, Ann Arbor, MI.
Purohit T; Department of Pathology, University of Michigan, Ann Arbor, MI.
Kempinska K; Department of Pathology, University of Michigan, Ann Arbor, MI.
Ropa J; Department of Microbiology and Immunology, School of Medicine, Indiana University, Indianapolis, IN; and.
Klossowski S; Department of Pathology, University of Michigan, Ann Arbor, MI.
Trotman W; Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Danet-Desnoyers G; Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Cierpicki T; Department of Pathology, University of Michigan, Ann Arbor, MI.
Grembecka J; Department of Pathology, University of Michigan, Ann Arbor, MI.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Dec 17; Vol. 136 (25), pp. 2958-2963.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/enzymology
Leukemia, Myeloid, Acute*/genetics
Models, Biological*
Mutation*
Proto-Oncogene Proteins*/antagonists & inhibitors
Proto-Oncogene Proteins*/genetics
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
fms-Like Tyrosine Kinase 3*/genetics
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Female ; Humans ; Male ; Protein Kinase Inhibitors/administration & dosage
Czasopismo naukowe
Tytuł :
Fms-Like Tyrosine Kinase 3-Independent Dendritic Cells Are Major Mediators of Th2 Immune Responses in Allergen-Induced Asthmatic Mice.
Autorzy :
Park SC; Department of Otorhinolaryngology-Head and Neck Surgery, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07441, Korea.
Shim D; Department of Microbiology, Yonsei University College of Medicine, Seoul 03722, Korea.
Kim H; Department of Microbiology, Yonsei University College of Medicine, Seoul 03722, Korea.; Brain Korea 21 Program for Leading Universities and Students (PLUS) Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea.
Bak Y; Department of Microbiology, Yonsei University College of Medicine, Seoul 03722, Korea.; Brain Korea 21 Program for Leading Universities and Students (PLUS) Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea.
Choi DY; Industry-Academic Cooperation Foundation, Hallym University, Chuncheon 24252, Korea.
Yoon JH; Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Korea.; Global Research Laboratory for Allergic Airway Diseases, Yonsei University College of Medicine, Seoul 03722, Korea.; The Airway Mucus Institute, Yonsei University College of Medicine, Seoul 03722, Korea.
Kim CH; Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Korea.; The Airway Mucus Institute, Yonsei University College of Medicine, Seoul 03722, Korea.
Shin SJ; Brain Korea 21 Program for Leading Universities and Students (PLUS) Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea.; Global Research Laboratory for Allergic Airway Diseases, Yonsei University College of Medicine, Seoul 03722, Korea.; Department of Microbiology, Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul 03722, Korea.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Dec 14; Vol. 21 (24). Date of Electronic Publication: 2020 Dec 14.
Typ publikacji :
Journal Article
MeSH Terms :
Asthma/*metabolism
Dendritic Cells/*metabolism
Th2 Cells/*metabolism
fms-Like Tyrosine Kinase 3/*metabolism
Adoptive Transfer ; Animals ; CD11b Antigen/metabolism ; Enzyme-Linked Immunosorbent Assay ; Female ; Flow Cytometry ; Mice ; Mice, Knockout ; OX40 Ligand/metabolism ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Autorzy :
Dzama MM; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Steiner M; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; German Consortia for Translational Cancer Research, Mainz, Germany.
Rausch J; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; German Consortia for Translational Cancer Research, Mainz, Germany.
Sasca D; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; German Consortia for Translational Cancer Research, Mainz, Germany.; University Cancer Center Mainz, Mainz, Germany.
Schönfeld J; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Kunz K; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Taubert MC; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
McGeehan GM; Syndax Pharmaceuticals, Inc, Waltham, MA.
Chen CW; Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA.
Mupo A; Welcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Wellcome Sanger Institute, Cambridge, United Kingdom.
Hähnel P; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; University Cancer Center Mainz, Mainz, Germany.
Theobald M; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; German Consortia for Translational Cancer Research, Mainz, Germany.; University Cancer Center Mainz, Mainz, Germany.
Kindler T; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; German Consortia for Translational Cancer Research, Mainz, Germany.; University Cancer Center Mainz, Mainz, Germany.
Koche RP; Center for Epigenetics Research, Memorial Sloan-Kettering Cancer Center, New York, NY.
Vassiliou GS; Welcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Wellcome Sanger Institute, Cambridge, United Kingdom.
Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; and.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Kühn MWM; Department of Hematology, Medical Oncology, and Pulmonary Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; German Consortia for Translational Cancer Research, Mainz, Germany.; University Cancer Center Mainz, Mainz, Germany.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Nov 19; Vol. 136 (21), pp. 2442-2456.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Gene Expression Regulation, Leukemic/*drug effects
Histone-Lysine N-Methyltransferase/*antagonists & inhibitors
Leukemia, Myeloid, Acute/*drug therapy
Myeloid-Lymphoid Leukemia Protein/*antagonists & inhibitors
Neoplasm Proteins/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Proto-Oncogene Proteins/*antagonists & inhibitors
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; Cell Line, Tumor ; Coculture Techniques ; Drug Synergism ; Humans ; Leukemia, Myeloid, Acute/genetics ; Mice ; Mice, Inbred NOD ; Myeloid Ecotropic Viral Integration Site 1 Protein/biosynthesis ; Myeloid Ecotropic Viral Integration Site 1 Protein/genetics ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Nuclear Proteins/genetics ; Phosphorylation ; Protein Kinase Inhibitors/pharmacology ; Protein Processing, Post-Translational ; Random Allocation ; Transcription, Genetic/drug effects ; fms-Like Tyrosine Kinase 3/biosynthesis ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Autorzy :
Gebru MT; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Wang HG; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA. .; Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA. .; Penn State College of Medicine, 500 University Drive, Hershey, PA, 17033, USA. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2020 Nov 19; Vol. 13 (1), pp. 155. Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Resistance, Neoplasm*/drug effects
Antineoplastic Agents/*pharmacology
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Antineoplastic Agents/therapeutic use ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Molecular Targeted Therapy ; Mutation/drug effects ; Protein Kinase Inhibitors/therapeutic use ; Signal Transduction/drug effects ; fms-Like Tyrosine Kinase 3/chemistry ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Autorzy :
Scholl S; Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, Germany.
Fleischmann M; Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, Germany.
Schnetzke U; Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, Germany.
Heidel FH; Innere Medizin C, Universitätsmedizin Greifswald, Sauerbruchstrasse, 17475 Greifswald, Germany.
Pokaż więcej
Źródło :
Cells [Cells] 2020 Nov 17; Vol. 9 (11). Date of Electronic Publication: 2020 Nov 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Aniline Compounds/therapeutic use ; Humans ; Pyrazines/therapeutic use ; Staurosporine/analogs & derivatives ; Staurosporine/therapeutic use ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations.
Autorzy :
Zhang G; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Sichuan 610041, China.
Zhang W; Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Sichuan 610041, China.
Shen C; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Sichuan 610041, China.
Nan J; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Sichuan 610041, China.
Chen M; Guangxi Wuzhou Pharmaceutical Co. Ltd, Wuzhou, Guangxi 543000, China.
Lai S; Guangxi Wuzhou Pharmaceutical Co. Ltd, Wuzhou, Guangxi 543000, China.
Zhong J; Guangxi Wuzhou Pharmaceutical Co. Ltd, Wuzhou, Guangxi 543000, China.
Li B; Guangxi Wuzhou Pharmaceutical Co. Ltd, Wuzhou, Guangxi 543000, China.
Wang T; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Sichuan 610041, China.
Wang Y; Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Sichuan 610041, China.
Yang S; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Sichuan 610041, China.
Li L; Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Sichuan 610041, China. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Nov 15; Vol. 30 (22), pp. 127532. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Discovery*
Drug Resistance, Neoplasm/*drug effects
Protein Kinase Inhibitors/*pharmacology
Small Molecule Libraries/*pharmacology
Urea/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Cell Line, Tumor ; Dose-Response Relationship, Drug ; Humans ; Molecular Structure ; Mutation ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Small Molecule Libraries/chemical synthesis ; Small Molecule Libraries/chemistry ; Structure-Activity Relationship ; Urea/analogs & derivatives ; Urea/chemistry ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks.
Autorzy :
Bär I; Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), Jena University Hospital, 07745 Jena, Germany.
Ast V; Institute for Clinical Chemistry, Medical Faculty Mannheim, Heidelberg University, 69117 Heidelberg, Germany.
Meyer D; Center for Infectious Diseases and Infection Control, Jena University Hospital, 07745 Jena, Germany.
König R; Center for Infectious Diseases and Infection Control, Jena University Hospital, 07745 Jena, Germany.; Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), 07745 Jena, Germany.
Rauner M; Department of Medicine III & Center for Healthy Aging, Technical University Dresden, 01069 Dresden, Germany.
Hofbauer LC; Department of Medicine III & Center for Healthy Aging, Technical University Dresden, 01069 Dresden, Germany.
Müller JP; Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), Jena University Hospital, 07745 Jena, Germany.
Pokaż więcej
Źródło :
Cells [Cells] 2020 Nov 09; Vol. 9 (11). Date of Electronic Publication: 2020 Nov 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Homeostasis*
Oncogenes*
Bone and Bones/*pathology
Cytokines/*metabolism
Leukemia, Myeloid, Acute/*pathology
fms-Like Tyrosine Kinase 3/*genetics
Animals ; Cell Line, Tumor ; Gene Duplication ; Gene Expression Profiling ; Gene Expression Regulation, Leukemic ; Hematopoietic Stem Cells/metabolism ; Humans ; Leukemia, Myeloid, Acute/genetics ; Mice ; Osteoblasts/metabolism ; Osteoblasts/pathology ; Osteoclasts/metabolism ; Osteoclasts/pathology ; Osteogenesis ; Prognosis ; RAW 264.7 Cells ; Signal Transduction ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe
Tytuł :
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Autorzy :
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zeng Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chen HC; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kelly MA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
McQueen T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wang RY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Nov; Vol. 95 (11), pp. 1296-1303. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Leukemia, Myeloid, Acute*/blood
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/mortality
Mutation*
fms-Like Tyrosine Kinase 3*/blood
fms-Like Tyrosine Kinase 3*/genetics
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Heterocyclic Compounds/administration & dosage ; Heterocyclic Compounds/adverse effects ; Humans ; Male ; Middle Aged ; Sorafenib/administration & dosage ; Sorafenib/adverse effects ; Survival Rate
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies